As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma .
Following on from advice received from the company, the timelines for this appraisal are currently to be confirmed and therefore the appraisal is suspended.
As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties as and when the situation changes.
| Status | Suspended |
| Process | STA 2018 |
| ID number | 1375 |
Project Team
| Project lead | Jenna Dilkes |
Email enquiries
- If you have any queries please email jenna.dilkes@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 04 October 2018 | Suspended. As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma . Following on from advice received from the company, the timelines for this appraisal are currently to be confirmed and therefore the appraisal is suspended. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 11 June 2018 - 09 July 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 24 April 2018 | In progress. DHSC referral received |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance